ログイン

3. ISBT

3. ISBT
96問 • 2年前
  • Yves Laure Pimentel
  • 通報

    問題一覧

  • 1

    ISBT –

    International Society of Blood Transfusion

  • 2

    ISBT – International Society of Blood Transfusion - The first three numbers represent the ______ (A.22) and the remaining three the antigenic specificity.

    SYSTEM

  • 3

    ISBT ?:ABO Blood Group System

    001

  • 4

    ISBT 001:

    ABO Blood Group System

  • 5

    discovered ABO

    Karl Landsteiner

  • 6

    Most IMPORTANT AND MOST IMMUNOGENIC

    ISBT 001:ABO Blood Group System

  • 7

    Only blood group with NATURALLY occurring antibody w/o prior exposure

    ISBT 001:ABO Blood Group System

  • 8

    = FOUNDATION to pre transfusion testing

    ABO compatibility

  • 9

    = leading cause of death in hemolytic transfusion rxn reported by FDA

    Wrong ABO transfusion

  • 10

    Wrong ABO transfusion = leading cause of death in ? reported by FDA

    hemolytic transfusion rxn

  • 11

    - is now considered the leading cause of transfusion-associated fatalities, surpassing ABO incompatibility and bacterial contamination

    TRALI TRANSFUSION RELATED ACUTE LUNG INJURY

  • 12

    TRALI

    TRANSFUSION RELATED ACUTE LUNG INJURY

  • 13

    Most fatal transfusion reaction

    ABO

  • 14

    ABO naturally Occurring Ab:

    IgM, IgG, and IgA

  • 15

    Formation of ABH Antigens H and Se Genes -

    CHROMOSOME 19

  • 16

    Formation of ABH Antigens ABO genes

    CHROMOSOME 9

  • 17

    - does not produce DETECTABLE Ag

    Amorph

  • 18

    SILENT GENES ARE

    JK/KIDD, O, LUTHERAN

  • 19

    Gene H Glycosyl Transferase

    L-fucosyl transferase

  • 20

    Gene A Glycosyl Transferase

    N-acetylgalactosaminyl Transferase

  • 21

    Gene B Glycosyl Transferase

    D-galactosyl transferase

  • 22

    Gene AB Glycosyl Transferase

    Both A and B

  • 23

    Gene AB Immunodominant sugar

    Both A and B

  • 24

    Gene A Immunodominant sugar

    N-acetyl-D-galactosamine

  • 25

    Gene B Immunodominant sugar

    D-galactose

  • 26

    Gene H Immunodominant sugar

    L-fucose

  • 27

    Gene H ANTIGEN

    H

  • 28

    Gene A ANTIGEN

    A

  • 29

    Gene B ANTIGEN

    B

  • 30

    Gene AB ANTIGEN

    AB

  • 31

    Greatest Amount of H to least

    A>A2>B>A2B>A1>A1B

  • 32

    Highest Incidence to Lowest:

    O>A>B>AB

  • 33

    ANTI H LECTIN FOR BOMBAY PHENOTYPE DETERMINATION

    ULEX EUROPEUS

  • 34

    ABO Grouping blood typing is

    PHENOTYPING

  • 35

    - Physical expression of genotype.

    Phenotype

  • 36

    uses commercial KNOWN anti-sera of known specificity

    Forward Typing

  • 37

    Forward Typing uses commercial ______ anti-sera of known specificity

    KNOWN

  • 38

    Detect ANTIGEN on RBC surface

    Forward Typing

  • 39

    Detect ANTIGEN on RBC surface

    Forward Typing

  • 40

    Forward Typing Reagents: COLOR 1.Anti A Dye = 2.Anti B Dye = 3.Anti D Dye =

    1. BLUE 2. YELLOW 3. COLORLESS

  • 41

    Backward Typing uses _________

    KNOWN RED CELLS SUSPENSION

  • 42

    uses KNOWN RED CELLS SUSPENSION

    Backward Typing

  • 43

    detects the presence of ANTIBODIES

    Backward Typing

  • 44

    Backward Typing detects the presence of ?

    ANTIBODIES

  • 45

    Backward Typing reagent __________ red cell suspension

    2.5% KNOWN O

  • 46

    v. Rh control: Patient cells in saline or ? – Used if patient is typed as AB+ in slide typing.

    6% albumin

  • 47

    Both Forward and reverse are done in __________

    ROOM TEMPERATURE

  • 48

    ANTIBODY THAT CAUSES SPONTANEOUS AGGLUTINATION

    AUTOAGGLUTINATE

  • 49

    A Subgroup DISCOVERED BY

    VON DUNGERN

  • 50

    = reacts w/Anti A but not Anti A1

    A2

  • 51

    = reacts w/Anti A & Anti A1

    A1

  • 52

    A2 and A2B individuals __________ in their serum. Therefore, they can be ___________ with A1 donors

    PRODUCE ANTI-A1 , INCOMPATIBLE

  • 53

    – naturally occurring IgM

    Anti A1

  • 54

    Anti A1 or A1B (SOURCE)– __________

    DOLICHOS BIFLORUS

  • 55

    A Subgroup _________ for Antibody screening

    NEGATIVE

  • 56

    A1 and A2 won't have equal reaction with Anti

    H

  • 57

    -A1 and A2 will have ____ reaction with Anti A,B

    positive

  • 58

    (Oh/Hnull)

    Bombay phenotype

  • 59

    Bombay phenotype (?)

    Oh/Hnull

  • 60

    Bhende in Bombay India

    Bombay phenotype

  • 61

    Bombay phenotype (Oh/Hnull) Type O has no __________

    H GENE

  • 62

    Anti H/O – __________

    ULEX UROPEUS

  • 63

    FUT 1 (? GENE)

    H

  • 64

    FUT 2 (? GENE)

    Se

  • 65

    FUT 3 (? GENE)

    LEWIS

  • 66

    NO agglutination w/Anti B and Anti AB but has B in saliva

    Bm

  • 67

    – No agglutination w/Anti B and Anti AB, secretors have H but no B in saliva

    Bel

  • 68

    ABO incompat have strong reaction (?)

    3+, 0+,4+

  • 69

    have strong reaction (3+, 0+,4+)

    ABO incompat

  • 70

    (mix field, 1+, 2+)

    ABO incompat reaction

  • 71

    Discrepancy weak reaction (?)

    mix field, 1+, 2+

  • 72

    ANTIBODY WEAK OR ABSENT -REVERSE TYPING PROBLEM - more common discrepancy

    Group I

  • 73

    Group I - ? WEAK OR ABSENT -REVERSE TYPING PROBLEM - more common discrepancy

    ANTIBODY

  • 74

    Group I - ANTIBODY WEAK OR ABSENT -? PROBLEM - more common discrepancy

    REVERSE TYPING

  • 75

    WHAT GROUP IS ASSOCIATED? agammaglobulinemia

    Group I

  • 76

    WHAT GROUP IS ASSOCIATED? hypogammaglobulinemia

    Group I

  • 77

    WHAT GROUP IS ASSOCIATED? immunosuppressive drugs

    Group I

  • 78

    -ANTIGEN WEAK OR ABSENT – FORWARD TYPING

    Group II

  • 79

    Group II -? WEAK OR ABSENT – FORWARD TYPING

    ANTIGEN

  • 80

    Group II -ANTIGEN WEAK OR ABSENT – ? TYPING

    FORWARD

  • 81

    Subgroups of A and B-Rem:

    Lectins

  • 82

    (Translocation at chrom 9-ABO Genes)

    Leukemia

  • 83

    Leukemia(Translocation at chrom ?-ABO Genes)

    9

  • 84

    (weakens ABH Ag)

    Hodgkins

  • 85

    – mixed cell population in a single individual

    Chimerism

  • 86

    – two sperm in one egg

    dispermy

  • 87

    -PROTEIN AND PLASMA ABNORMALITIES ROULEAUX/PSEUDOAGGLUTININ

    Group III

  • 88

    Group III - ->ROULEAUX/PSEUDOAGGLUTININ

    PROTEIN AND PLASMA ABNORMALITIES

  • 89

    Group III -PROTEIN AND PLASMA ABNORMALITIES ->

    ROULEAUX/PSEUDOAGGLUTININ

  • 90

    Unexpected Ab Reaction (Between Forward and Reverse)

    Group III -PROTEIN AND PLASMA ABNORMALITIES ROULEAUX/PSEUDOAGGLUTININ

  • 91

    Wharton’s Jelly

    Group III -PROTEIN AND PLASMA ABNORMALITIES ROULEAUX/PSEUDOAGGLUTININ

  • 92

    - MISCELLANEOUS PROBLEM

    Group IV

  • 93

    Group IV -

    MISCELLANEOUS PROBLEM

  • 94

    Unexpected Antigen Reaction (bet.Forward and reverse)

    Group IV - MISCELLANEOUS PROBLEM

  • 95

    Cold Reactive Antibody

    Group IV - MISCELLANEOUS PROBLEM

  • 96

    Polyagglutination

    Group IV - MISCELLANEOUS PROBLEM

  • other names parasitology

    other names parasitology

    Yves Laure Pimentel · 70問 · 2年前

    other names parasitology

    other names parasitology

    70問 • 2年前
    Yves Laure Pimentel

    PARASITOLOGY

    PARASITOLOGY

    Yves Laure Pimentel · 111問 · 2年前

    PARASITOLOGY

    PARASITOLOGY

    111問 • 2年前
    Yves Laure Pimentel

    HTMLBE

    HTMLBE

    Yves Laure Pimentel · 64問 · 2年前

    HTMLBE

    HTMLBE

    64問 • 2年前
    Yves Laure Pimentel

    CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR

    CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR

    Yves Laure Pimentel · 61問 · 2年前

    CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR

    CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR

    61問 • 2年前
    Yves Laure Pimentel

    HISTOPATHOLOGY

    HISTOPATHOLOGY

    Yves Laure Pimentel · 69問 · 2年前

    HISTOPATHOLOGY

    HISTOPATHOLOGY

    69問 • 2年前
    Yves Laure Pimentel

    CC-2 SPECTROPHOTOMETRY

    CC-2 SPECTROPHOTOMETRY

    Yves Laure Pimentel · 100問 · 2年前

    CC-2 SPECTROPHOTOMETRY

    CC-2 SPECTROPHOTOMETRY

    100問 • 2年前
    Yves Laure Pimentel

    CC-3 ELECTROPHORESIS

    CC-3 ELECTROPHORESIS

    Yves Laure Pimentel · 41問 · 2年前

    CC-3 ELECTROPHORESIS

    CC-3 ELECTROPHORESIS

    41問 • 2年前
    Yves Laure Pimentel

    AUBF LAB SAFETY

    AUBF LAB SAFETY

    Yves Laure Pimentel · 87問 · 2年前

    AUBF LAB SAFETY

    AUBF LAB SAFETY

    87問 • 2年前
    Yves Laure Pimentel

    CSF 1

    CSF 1

    Yves Laure Pimentel · 100問 · 2年前

    CSF 1

    CSF 1

    100問 • 2年前
    Yves Laure Pimentel

    CSF 2

    CSF 2

    Yves Laure Pimentel · 82問 · 2年前

    CSF 2

    CSF 2

    82問 • 2年前
    Yves Laure Pimentel

    SEMEN 1

    SEMEN 1

    Yves Laure Pimentel · 100問 · 2年前

    SEMEN 1

    SEMEN 1

    100問 • 2年前
    Yves Laure Pimentel

    SEMEN 2

    SEMEN 2

    Yves Laure Pimentel · 7問 · 2年前

    SEMEN 2

    SEMEN 2

    7問 • 2年前
    Yves Laure Pimentel

    SYNOVIAL FLUID 1

    SYNOVIAL FLUID 1

    Yves Laure Pimentel · 100問 · 2年前

    SYNOVIAL FLUID 1

    SYNOVIAL FLUID 1

    100問 • 2年前
    Yves Laure Pimentel

    SYNOVIAL FLUID 2

    SYNOVIAL FLUID 2

    Yves Laure Pimentel · 6問 · 2年前

    SYNOVIAL FLUID 2

    SYNOVIAL FLUID 2

    6問 • 2年前
    Yves Laure Pimentel

    SEROUS FLUID

    SEROUS FLUID

    Yves Laure Pimentel · 25問 · 2年前

    SEROUS FLUID

    SEROUS FLUID

    25問 • 2年前
    Yves Laure Pimentel

    PLEURAL FLUID

    PLEURAL FLUID

    Yves Laure Pimentel · 44問 · 2年前

    PLEURAL FLUID

    PLEURAL FLUID

    44問 • 2年前
    Yves Laure Pimentel

    PERICARDIAL FLUID

    PERICARDIAL FLUID

    Yves Laure Pimentel · 18問 · 2年前

    PERICARDIAL FLUID

    PERICARDIAL FLUID

    18問 • 2年前
    Yves Laure Pimentel

    PERITONEAL FLUID/ ASCITIC FLUID

    PERITONEAL FLUID/ ASCITIC FLUID

    Yves Laure Pimentel · 30問 · 2年前

    PERITONEAL FLUID/ ASCITIC FLUID

    PERITONEAL FLUID/ ASCITIC FLUID

    30問 • 2年前
    Yves Laure Pimentel

    AMNIOTIC FLUID

    AMNIOTIC FLUID

    Yves Laure Pimentel · 92問 · 2年前

    AMNIOTIC FLUID

    AMNIOTIC FLUID

    92問 • 2年前
    Yves Laure Pimentel

    FECALYSIS

    FECALYSIS

    Yves Laure Pimentel · 80問 · 2年前

    FECALYSIS

    FECALYSIS

    80問 • 2年前
    Yves Laure Pimentel

    OTHER BODY FLUIDS

    OTHER BODY FLUIDS

    Yves Laure Pimentel · 89問 · 2年前

    OTHER BODY FLUIDS

    OTHER BODY FLUIDS

    89問 • 2年前
    Yves Laure Pimentel

    MTLBE- SUHO NOTES

    MTLBE- SUHO NOTES

    Yves Laure Pimentel · 86問 · 2年前

    MTLBE- SUHO NOTES

    MTLBE- SUHO NOTES

    86問 • 2年前
    Yves Laure Pimentel

    MTLBE..

    MTLBE..

    Yves Laure Pimentel · 35問 · 2年前

    MTLBE..

    MTLBE..

    35問 • 2年前
    Yves Laure Pimentel

    CC- CHROMATOGRAPHY

    CC- CHROMATOGRAPHY

    Yves Laure Pimentel · 19問 · 1年前

    CC- CHROMATOGRAPHY

    CC- CHROMATOGRAPHY

    19問 • 1年前
    Yves Laure Pimentel

    CC-OSMOMETRY

    CC-OSMOMETRY

    Yves Laure Pimentel · 14問 · 1年前

    CC-OSMOMETRY

    CC-OSMOMETRY

    14問 • 1年前
    Yves Laure Pimentel

    CC-ELECTROCHEMISTRY TECHNIQUES

    CC-ELECTROCHEMISTRY TECHNIQUES

    Yves Laure Pimentel · 43問 · 1年前

    CC-ELECTROCHEMISTRY TECHNIQUES

    CC-ELECTROCHEMISTRY TECHNIQUES

    43問 • 1年前
    Yves Laure Pimentel

    CC- CARBOHYDRATES

    CC- CARBOHYDRATES

    Yves Laure Pimentel · 49問 · 2年前

    CC- CARBOHYDRATES

    CC- CARBOHYDRATES

    49問 • 2年前
    Yves Laure Pimentel

    CC- DIABETES MELLITUS

    CC- DIABETES MELLITUS

    Yves Laure Pimentel · 97問 · 2年前

    CC- DIABETES MELLITUS

    CC- DIABETES MELLITUS

    97問 • 2年前
    Yves Laure Pimentel

    MAJOR LIPOPROTEINS

    MAJOR LIPOPROTEINS

    Yves Laure Pimentel · 57問 · 2年前

    MAJOR LIPOPROTEINS

    MAJOR LIPOPROTEINS

    57問 • 2年前
    Yves Laure Pimentel

    MINOR LIPOPROTEINS

    MINOR LIPOPROTEINS

    Yves Laure Pimentel · 63問 · 2年前

    MINOR LIPOPROTEINS

    MINOR LIPOPROTEINS

    63問 • 2年前
    Yves Laure Pimentel

    PROTEINS

    PROTEINS

    Yves Laure Pimentel · 37問 · 2年前

    PROTEINS

    PROTEINS

    37問 • 2年前
    Yves Laure Pimentel

    PLASMA PROTEINS 1

    PLASMA PROTEINS 1

    Yves Laure Pimentel · 91問 · 2年前

    PLASMA PROTEINS 1

    PLASMA PROTEINS 1

    91問 • 2年前
    Yves Laure Pimentel

    PLASMA PROTEINS 2 (ALPHA 2 REGION)

    PLASMA PROTEINS 2 (ALPHA 2 REGION)

    Yves Laure Pimentel · 98問 · 2年前

    PLASMA PROTEINS 2 (ALPHA 2 REGION)

    PLASMA PROTEINS 2 (ALPHA 2 REGION)

    98問 • 2年前
    Yves Laure Pimentel

    MISCELLANEOUS PROTEINS

    MISCELLANEOUS PROTEINS

    Yves Laure Pimentel · 61問 · 2年前

    MISCELLANEOUS PROTEINS

    MISCELLANEOUS PROTEINS

    61問 • 2年前
    Yves Laure Pimentel

    Liver Function Test 1

    Liver Function Test 1

    Yves Laure Pimentel · 100問 · 2年前

    Liver Function Test 1

    Liver Function Test 1

    100問 • 2年前
    Yves Laure Pimentel

    Liver Function Test 2

    Liver Function Test 2

    Yves Laure Pimentel · 96問 · 2年前

    Liver Function Test 2

    Liver Function Test 2

    96問 • 2年前
    Yves Laure Pimentel

    TUMOR MARKERS

    TUMOR MARKERS

    Yves Laure Pimentel · 33問 · 2年前

    TUMOR MARKERS

    TUMOR MARKERS

    33問 • 2年前
    Yves Laure Pimentel

    KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE

    KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE

    Yves Laure Pimentel · 41問 · 2年前

    KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE

    KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE

    41問 • 2年前
    Yves Laure Pimentel

    GLYCOGEN STORAGE DISEASES

    GLYCOGEN STORAGE DISEASES

    Yves Laure Pimentel · 17問 · 2年前

    GLYCOGEN STORAGE DISEASES

    GLYCOGEN STORAGE DISEASES

    17問 • 2年前
    Yves Laure Pimentel

    LIPID STORAGE DISEASES

    LIPID STORAGE DISEASES

    Yves Laure Pimentel · 14問 · 2年前

    LIPID STORAGE DISEASES

    LIPID STORAGE DISEASES

    14問 • 2年前
    Yves Laure Pimentel

    PROTEINS

    PROTEINS

    Yves Laure Pimentel · 71問 · 2年前

    PROTEINS

    PROTEINS

    71問 • 2年前
    Yves Laure Pimentel

    QUICK FIRE- ELECTRODES

    QUICK FIRE- ELECTRODES

    Yves Laure Pimentel · 7問 · 2年前

    QUICK FIRE- ELECTRODES

    QUICK FIRE- ELECTRODES

    7問 • 2年前
    Yves Laure Pimentel

    ELECTROLYTES

    ELECTROLYTES

    Yves Laure Pimentel · 10問 · 2年前

    ELECTROLYTES

    ELECTROLYTES

    10問 • 2年前
    Yves Laure Pimentel

    DRUGS

    DRUGS

    Yves Laure Pimentel · 27問 · 2年前

    DRUGS

    DRUGS

    27問 • 2年前
    Yves Laure Pimentel

    TOXIC AGENTS:

    TOXIC AGENTS:

    Yves Laure Pimentel · 12問 · 2年前

    TOXIC AGENTS:

    TOXIC AGENTS:

    12問 • 2年前
    Yves Laure Pimentel

    HEMATOLOGY 1 (HEMATOPOIESIS 1)

    HEMATOLOGY 1 (HEMATOPOIESIS 1)

    Yves Laure Pimentel · 100問 · 2年前

    HEMATOLOGY 1 (HEMATOPOIESIS 1)

    HEMATOLOGY 1 (HEMATOPOIESIS 1)

    100問 • 2年前
    Yves Laure Pimentel

    HEMATOLOGY (HEMATOPOIESIS 2)

    HEMATOLOGY (HEMATOPOIESIS 2)

    Yves Laure Pimentel · 29問 · 2年前

    HEMATOLOGY (HEMATOPOIESIS 2)

    HEMATOLOGY (HEMATOPOIESIS 2)

    29問 • 2年前
    Yves Laure Pimentel

    hema diseases

    hema diseases

    Yves Laure Pimentel · 25問 · 2年前

    hema diseases

    hema diseases

    25問 • 2年前
    Yves Laure Pimentel

    AML

    AML

    Yves Laure Pimentel · 43問 · 2年前

    AML

    AML

    43問 • 2年前
    Yves Laure Pimentel

    GLOBIN SYNTHESIS

    GLOBIN SYNTHESIS

    Yves Laure Pimentel · 71問 · 2年前

    GLOBIN SYNTHESIS

    GLOBIN SYNTHESIS

    71問 • 2年前
    Yves Laure Pimentel

    HEMATOLOGY REFERENCE RANGES

    HEMATOLOGY REFERENCE RANGES

    Yves Laure Pimentel · 31問 · 2年前

    HEMATOLOGY REFERENCE RANGES

    HEMATOLOGY REFERENCE RANGES

    31問 • 2年前
    Yves Laure Pimentel

    DISORDERS OF PRIMARY HEMOSTASIS

    DISORDERS OF PRIMARY HEMOSTASIS

    Yves Laure Pimentel · 34問 · 2年前

    DISORDERS OF PRIMARY HEMOSTASIS

    DISORDERS OF PRIMARY HEMOSTASIS

    34問 • 2年前
    Yves Laure Pimentel

    PLATELET DISORDERS

    PLATELET DISORDERS

    Yves Laure Pimentel · 37問 · 2年前

    PLATELET DISORDERS

    PLATELET DISORDERS

    37問 • 2年前
    Yves Laure Pimentel

    CHARACTERISTICS OF CLOTTING FACTORS

    CHARACTERISTICS OF CLOTTING FACTORS

    Yves Laure Pimentel · 100問 · 2年前

    CHARACTERISTICS OF CLOTTING FACTORS

    CHARACTERISTICS OF CLOTTING FACTORS

    100問 • 2年前
    Yves Laure Pimentel

    4. CLASSIFICATION OF MACROPHAGE

    4. CLASSIFICATION OF MACROPHAGE

    Yves Laure Pimentel · 12問 · 2年前

    4. CLASSIFICATION OF MACROPHAGE

    4. CLASSIFICATION OF MACROPHAGE

    12問 • 2年前
    Yves Laure Pimentel

    3. NATURAL OR INNATE IMMUNITY

    3. NATURAL OR INNATE IMMUNITY

    Yves Laure Pimentel · 39問 · 2年前

    3. NATURAL OR INNATE IMMUNITY

    3. NATURAL OR INNATE IMMUNITY

    39問 • 2年前
    Yves Laure Pimentel

    5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)

    5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)

    Yves Laure Pimentel · 55問 · 2年前

    5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)

    5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)

    55問 • 2年前
    Yves Laure Pimentel

    6. PHAGOCYTOSIS Chemotaxis

    6. PHAGOCYTOSIS Chemotaxis

    Yves Laure Pimentel · 37問 · 2年前

    6. PHAGOCYTOSIS Chemotaxis

    6. PHAGOCYTOSIS Chemotaxis

    37問 • 2年前
    Yves Laure Pimentel

    8. NATURE OF ANTIGEN

    8. NATURE OF ANTIGEN

    Yves Laure Pimentel · 44問 · 2年前

    8. NATURE OF ANTIGEN

    8. NATURE OF ANTIGEN

    44問 • 2年前
    Yves Laure Pimentel

    9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN

    9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN

    Yves Laure Pimentel · 50問 · 2年前

    9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN

    9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN

    50問 • 2年前
    Yves Laure Pimentel

    1. HISTORY

    1. HISTORY

    Yves Laure Pimentel · 69問 · 2年前

    1. HISTORY

    1. HISTORY

    69問 • 2年前
    Yves Laure Pimentel

    2. TYPES OF IMMUNITY

    2. TYPES OF IMMUNITY

    Yves Laure Pimentel · 38問 · 2年前

    2. TYPES OF IMMUNITY

    2. TYPES OF IMMUNITY

    38問 • 2年前
    Yves Laure Pimentel

    7. PHAGOCYTOSIS Engulfment and Digestion

    7. PHAGOCYTOSIS Engulfment and Digestion

    Yves Laure Pimentel · 21問 · 2年前

    7. PHAGOCYTOSIS Engulfment and Digestion

    7. PHAGOCYTOSIS Engulfment and Digestion

    21問 • 2年前
    Yves Laure Pimentel

    8. PHAGOCYTOSIS EXOCYTOSIS

    8. PHAGOCYTOSIS EXOCYTOSIS

    Yves Laure Pimentel · 15問 · 2年前

    8. PHAGOCYTOSIS EXOCYTOSIS

    8. PHAGOCYTOSIS EXOCYTOSIS

    15問 • 2年前
    Yves Laure Pimentel

    10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)

    10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)

    Yves Laure Pimentel · 32問 · 2年前

    10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)

    10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)

    32問 • 2年前
    Yves Laure Pimentel

    11. TRANSPLANTATION IMMUNOLOGY

    11. TRANSPLANTATION IMMUNOLOGY

    Yves Laure Pimentel · 30問 · 2年前

    11. TRANSPLANTATION IMMUNOLOGY

    11. TRANSPLANTATION IMMUNOLOGY

    30問 • 2年前
    Yves Laure Pimentel

    2. LYMPHOID ORGANS

    2. LYMPHOID ORGANS

    Yves Laure Pimentel · 38問 · 2年前

    2. LYMPHOID ORGANS

    2. LYMPHOID ORGANS

    38問 • 2年前
    Yves Laure Pimentel

    3. CLUSTER OF DIFFERENTIATION

    3. CLUSTER OF DIFFERENTIATION

    Yves Laure Pimentel · 48問 · 2年前

    3. CLUSTER OF DIFFERENTIATION

    3. CLUSTER OF DIFFERENTIATION

    48問 • 2年前
    Yves Laure Pimentel

    4. T-CELL DIFFERENTIATION

    4. T-CELL DIFFERENTIATION

    Yves Laure Pimentel · 35問 · 2年前

    4. T-CELL DIFFERENTIATION

    4. T-CELL DIFFERENTIATION

    35問 • 2年前
    Yves Laure Pimentel

    5. T CELL IMMUNODEFICIENCIES

    5. T CELL IMMUNODEFICIENCIES

    Yves Laure Pimentel · 18問 · 2年前

    5. T CELL IMMUNODEFICIENCIES

    5. T CELL IMMUNODEFICIENCIES

    18問 • 2年前
    Yves Laure Pimentel

    6. STAGES IN B-CELL DIFFERENTIATION  PROPIMAP

    6. STAGES IN B-CELL DIFFERENTIATION  PROPIMAP

    Yves Laure Pimentel · 44問 · 2年前

    6. STAGES IN B-CELL DIFFERENTIATION  PROPIMAP

    6. STAGES IN B-CELL DIFFERENTIATION  PROPIMAP

    44問 • 2年前
    Yves Laure Pimentel

    7. B CELL IMMUNODEFICIENCIES

    7. B CELL IMMUNODEFICIENCIES

    Yves Laure Pimentel · 23問 · 2年前

    7. B CELL IMMUNODEFICIENCIES

    7. B CELL IMMUNODEFICIENCIES

    23問 • 2年前
    Yves Laure Pimentel

    8. COMBINED T CELL AND B CELL DEFICIENCIES

    8. COMBINED T CELL AND B CELL DEFICIENCIES

    Yves Laure Pimentel · 34問 · 2年前

    8. COMBINED T CELL AND B CELL DEFICIENCIES

    8. COMBINED T CELL AND B CELL DEFICIENCIES

    34問 • 2年前
    Yves Laure Pimentel

    9. COMPARISON OF T AND B CELLS

    9. COMPARISON OF T AND B CELLS

    Yves Laure Pimentel · 12問 · 2年前

    9. COMPARISON OF T AND B CELLS

    9. COMPARISON OF T AND B CELLS

    12問 • 2年前
    Yves Laure Pimentel

    10. LABORATORY IDENTIFICATION OF LYMPHOCYTES

    10. LABORATORY IDENTIFICATION OF LYMPHOCYTES

    Yves Laure Pimentel · 16問 · 2年前

    10. LABORATORY IDENTIFICATION OF LYMPHOCYTES

    10. LABORATORY IDENTIFICATION OF LYMPHOCYTES

    16問 • 2年前
    Yves Laure Pimentel

    11. NATURAL KILLER CELLS OR THIRD POPULATION CELL

    11. NATURAL KILLER CELLS OR THIRD POPULATION CELL

    Yves Laure Pimentel · 15問 · 2年前

    11. NATURAL KILLER CELLS OR THIRD POPULATION CELL

    11. NATURAL KILLER CELLS OR THIRD POPULATION CELL

    15問 • 2年前
    Yves Laure Pimentel

    12. ANTIBODY

    12. ANTIBODY

    Yves Laure Pimentel · 79問 · 2年前

    12. ANTIBODY

    12. ANTIBODY

    79問 • 2年前
    Yves Laure Pimentel

    13. TYPES OF ANTIBODIES

    13. TYPES OF ANTIBODIES

    Yves Laure Pimentel · 97問 · 2年前

    13. TYPES OF ANTIBODIES

    13. TYPES OF ANTIBODIES

    97問 • 2年前
    Yves Laure Pimentel

    14. MONOCLONAL ANTIBODIES

    14. MONOCLONAL ANTIBODIES

    Yves Laure Pimentel · 11問 · 2年前

    14. MONOCLONAL ANTIBODIES

    14. MONOCLONAL ANTIBODIES

    11問 • 2年前
    Yves Laure Pimentel

    1. INTERLEUKINS

    1. INTERLEUKINS

    Yves Laure Pimentel · 23問 · 2年前

    1. INTERLEUKINS

    1. INTERLEUKINS

    23問 • 2年前
    Yves Laure Pimentel

    2. INTERFERONS

    2. INTERFERONS

    Yves Laure Pimentel · 28問 · 2年前

    2. INTERFERONS

    2. INTERFERONS

    28問 • 2年前
    Yves Laure Pimentel

    3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY

    3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY

    Yves Laure Pimentel · 8問 · 2年前

    3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY

    3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY

    8問 • 2年前
    Yves Laure Pimentel

    4. COMPLEMENT SYSTEM

    4. COMPLEMENT SYSTEM

    Yves Laure Pimentel · 19問 · 2年前

    4. COMPLEMENT SYSTEM

    4. COMPLEMENT SYSTEM

    19問 • 2年前
    Yves Laure Pimentel

    15. COMPLEMENT SYSTEM

    15. COMPLEMENT SYSTEM

    Yves Laure Pimentel · 76問 · 2年前

    15. COMPLEMENT SYSTEM

    15. COMPLEMENT SYSTEM

    76問 • 2年前
    Yves Laure Pimentel

    16. SYSTEM CONTROLS/COMPLEMENT REGULATION

    16. SYSTEM CONTROLS/COMPLEMENT REGULATION

    Yves Laure Pimentel · 21問 · 2年前

    16. SYSTEM CONTROLS/COMPLEMENT REGULATION

    16. SYSTEM CONTROLS/COMPLEMENT REGULATION

    21問 • 2年前
    Yves Laure Pimentel

    17. COMPLEMENT AND DISEASE STATES

    17. COMPLEMENT AND DISEASE STATES

    Yves Laure Pimentel · 29問 · 2年前

    17. COMPLEMENT AND DISEASE STATES

    17. COMPLEMENT AND DISEASE STATES

    29問 • 2年前
    Yves Laure Pimentel

    18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)

    18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)

    Yves Laure Pimentel · 19問 · 2年前

    18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)

    18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)

    19問 • 2年前
    Yves Laure Pimentel

    19. CYTOKINES

    19. CYTOKINES

    Yves Laure Pimentel · 22問 · 2年前

    19. CYTOKINES

    19. CYTOKINES

    22問 • 2年前
    Yves Laure Pimentel

    20. INTERLEUKINS

    20. INTERLEUKINS

    Yves Laure Pimentel · 24問 · 2年前

    20. INTERLEUKINS

    20. INTERLEUKINS

    24問 • 2年前
    Yves Laure Pimentel

    21. INTERFERONS, TNF, TGF, CHEMOKINE

    21. INTERFERONS, TNF, TGF, CHEMOKINE

    Yves Laure Pimentel · 21問 · 2年前

    21. INTERFERONS, TNF, TGF, CHEMOKINE

    21. INTERFERONS, TNF, TGF, CHEMOKINE

    21問 • 2年前
    Yves Laure Pimentel

    1. SERO

    1. SERO

    Yves Laure Pimentel · 54問 · 2年前

    1. SERO

    1. SERO

    54問 • 2年前
    Yves Laure Pimentel

    2. PRECIPITATION

    2. PRECIPITATION

    Yves Laure Pimentel · 38問 · 2年前

    2. PRECIPITATION

    2. PRECIPITATION

    38問 • 2年前
    Yves Laure Pimentel

    3. PASSIVE IMMUNODIFFUSION

    3. PASSIVE IMMUNODIFFUSION

    Yves Laure Pimentel · 17問 · 2年前

    3. PASSIVE IMMUNODIFFUSION

    3. PASSIVE IMMUNODIFFUSION

    17問 • 2年前
    Yves Laure Pimentel

    4. OUCHTERLONY

    4. OUCHTERLONY

    Yves Laure Pimentel · 15問 · 2年前

    4. OUCHTERLONY

    4. OUCHTERLONY

    15問 • 2年前
    Yves Laure Pimentel

    5. ELECTROPHORETIC TECHNIQUE

    5. ELECTROPHORETIC TECHNIQUE

    Yves Laure Pimentel · 9問 · 2年前

    5. ELECTROPHORETIC TECHNIQUE

    5. ELECTROPHORETIC TECHNIQUE

    9問 • 2年前
    Yves Laure Pimentel

    6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)

    6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)

    Yves Laure Pimentel · 11問 · 2年前

    6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)

    6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)

    11問 • 2年前
    Yves Laure Pimentel

    7. IMMUNOFIXATION ELECTROPHORESIS

    7. IMMUNOFIXATION ELECTROPHORESIS

    Yves Laure Pimentel · 29問 · 2年前

    7. IMMUNOFIXATION ELECTROPHORESIS

    7. IMMUNOFIXATION ELECTROPHORESIS

    29問 • 2年前
    Yves Laure Pimentel

    問題一覧

  • 1

    ISBT –

    International Society of Blood Transfusion

  • 2

    ISBT – International Society of Blood Transfusion - The first three numbers represent the ______ (A.22) and the remaining three the antigenic specificity.

    SYSTEM

  • 3

    ISBT ?:ABO Blood Group System

    001

  • 4

    ISBT 001:

    ABO Blood Group System

  • 5

    discovered ABO

    Karl Landsteiner

  • 6

    Most IMPORTANT AND MOST IMMUNOGENIC

    ISBT 001:ABO Blood Group System

  • 7

    Only blood group with NATURALLY occurring antibody w/o prior exposure

    ISBT 001:ABO Blood Group System

  • 8

    = FOUNDATION to pre transfusion testing

    ABO compatibility

  • 9

    = leading cause of death in hemolytic transfusion rxn reported by FDA

    Wrong ABO transfusion

  • 10

    Wrong ABO transfusion = leading cause of death in ? reported by FDA

    hemolytic transfusion rxn

  • 11

    - is now considered the leading cause of transfusion-associated fatalities, surpassing ABO incompatibility and bacterial contamination

    TRALI TRANSFUSION RELATED ACUTE LUNG INJURY

  • 12

    TRALI

    TRANSFUSION RELATED ACUTE LUNG INJURY

  • 13

    Most fatal transfusion reaction

    ABO

  • 14

    ABO naturally Occurring Ab:

    IgM, IgG, and IgA

  • 15

    Formation of ABH Antigens H and Se Genes -

    CHROMOSOME 19

  • 16

    Formation of ABH Antigens ABO genes

    CHROMOSOME 9

  • 17

    - does not produce DETECTABLE Ag

    Amorph

  • 18

    SILENT GENES ARE

    JK/KIDD, O, LUTHERAN

  • 19

    Gene H Glycosyl Transferase

    L-fucosyl transferase

  • 20

    Gene A Glycosyl Transferase

    N-acetylgalactosaminyl Transferase

  • 21

    Gene B Glycosyl Transferase

    D-galactosyl transferase

  • 22

    Gene AB Glycosyl Transferase

    Both A and B

  • 23

    Gene AB Immunodominant sugar

    Both A and B

  • 24

    Gene A Immunodominant sugar

    N-acetyl-D-galactosamine

  • 25

    Gene B Immunodominant sugar

    D-galactose

  • 26

    Gene H Immunodominant sugar

    L-fucose

  • 27

    Gene H ANTIGEN

    H

  • 28

    Gene A ANTIGEN

    A

  • 29

    Gene B ANTIGEN

    B

  • 30

    Gene AB ANTIGEN

    AB

  • 31

    Greatest Amount of H to least

    A>A2>B>A2B>A1>A1B

  • 32

    Highest Incidence to Lowest:

    O>A>B>AB

  • 33

    ANTI H LECTIN FOR BOMBAY PHENOTYPE DETERMINATION

    ULEX EUROPEUS

  • 34

    ABO Grouping blood typing is

    PHENOTYPING

  • 35

    - Physical expression of genotype.

    Phenotype

  • 36

    uses commercial KNOWN anti-sera of known specificity

    Forward Typing

  • 37

    Forward Typing uses commercial ______ anti-sera of known specificity

    KNOWN

  • 38

    Detect ANTIGEN on RBC surface

    Forward Typing

  • 39

    Detect ANTIGEN on RBC surface

    Forward Typing

  • 40

    Forward Typing Reagents: COLOR 1.Anti A Dye = 2.Anti B Dye = 3.Anti D Dye =

    1. BLUE 2. YELLOW 3. COLORLESS

  • 41

    Backward Typing uses _________

    KNOWN RED CELLS SUSPENSION

  • 42

    uses KNOWN RED CELLS SUSPENSION

    Backward Typing

  • 43

    detects the presence of ANTIBODIES

    Backward Typing

  • 44

    Backward Typing detects the presence of ?

    ANTIBODIES

  • 45

    Backward Typing reagent __________ red cell suspension

    2.5% KNOWN O

  • 46

    v. Rh control: Patient cells in saline or ? – Used if patient is typed as AB+ in slide typing.

    6% albumin

  • 47

    Both Forward and reverse are done in __________

    ROOM TEMPERATURE

  • 48

    ANTIBODY THAT CAUSES SPONTANEOUS AGGLUTINATION

    AUTOAGGLUTINATE

  • 49

    A Subgroup DISCOVERED BY

    VON DUNGERN

  • 50

    = reacts w/Anti A but not Anti A1

    A2

  • 51

    = reacts w/Anti A & Anti A1

    A1

  • 52

    A2 and A2B individuals __________ in their serum. Therefore, they can be ___________ with A1 donors

    PRODUCE ANTI-A1 , INCOMPATIBLE

  • 53

    – naturally occurring IgM

    Anti A1

  • 54

    Anti A1 or A1B (SOURCE)– __________

    DOLICHOS BIFLORUS

  • 55

    A Subgroup _________ for Antibody screening

    NEGATIVE

  • 56

    A1 and A2 won't have equal reaction with Anti

    H

  • 57

    -A1 and A2 will have ____ reaction with Anti A,B

    positive

  • 58

    (Oh/Hnull)

    Bombay phenotype

  • 59

    Bombay phenotype (?)

    Oh/Hnull

  • 60

    Bhende in Bombay India

    Bombay phenotype

  • 61

    Bombay phenotype (Oh/Hnull) Type O has no __________

    H GENE

  • 62

    Anti H/O – __________

    ULEX UROPEUS

  • 63

    FUT 1 (? GENE)

    H

  • 64

    FUT 2 (? GENE)

    Se

  • 65

    FUT 3 (? GENE)

    LEWIS

  • 66

    NO agglutination w/Anti B and Anti AB but has B in saliva

    Bm

  • 67

    – No agglutination w/Anti B and Anti AB, secretors have H but no B in saliva

    Bel

  • 68

    ABO incompat have strong reaction (?)

    3+, 0+,4+

  • 69

    have strong reaction (3+, 0+,4+)

    ABO incompat

  • 70

    (mix field, 1+, 2+)

    ABO incompat reaction

  • 71

    Discrepancy weak reaction (?)

    mix field, 1+, 2+

  • 72

    ANTIBODY WEAK OR ABSENT -REVERSE TYPING PROBLEM - more common discrepancy

    Group I

  • 73

    Group I - ? WEAK OR ABSENT -REVERSE TYPING PROBLEM - more common discrepancy

    ANTIBODY

  • 74

    Group I - ANTIBODY WEAK OR ABSENT -? PROBLEM - more common discrepancy

    REVERSE TYPING

  • 75

    WHAT GROUP IS ASSOCIATED? agammaglobulinemia

    Group I

  • 76

    WHAT GROUP IS ASSOCIATED? hypogammaglobulinemia

    Group I

  • 77

    WHAT GROUP IS ASSOCIATED? immunosuppressive drugs

    Group I

  • 78

    -ANTIGEN WEAK OR ABSENT – FORWARD TYPING

    Group II

  • 79

    Group II -? WEAK OR ABSENT – FORWARD TYPING

    ANTIGEN

  • 80

    Group II -ANTIGEN WEAK OR ABSENT – ? TYPING

    FORWARD

  • 81

    Subgroups of A and B-Rem:

    Lectins

  • 82

    (Translocation at chrom 9-ABO Genes)

    Leukemia

  • 83

    Leukemia(Translocation at chrom ?-ABO Genes)

    9

  • 84

    (weakens ABH Ag)

    Hodgkins

  • 85

    – mixed cell population in a single individual

    Chimerism

  • 86

    – two sperm in one egg

    dispermy

  • 87

    -PROTEIN AND PLASMA ABNORMALITIES ROULEAUX/PSEUDOAGGLUTININ

    Group III

  • 88

    Group III - ->ROULEAUX/PSEUDOAGGLUTININ

    PROTEIN AND PLASMA ABNORMALITIES

  • 89

    Group III -PROTEIN AND PLASMA ABNORMALITIES ->

    ROULEAUX/PSEUDOAGGLUTININ

  • 90

    Unexpected Ab Reaction (Between Forward and Reverse)

    Group III -PROTEIN AND PLASMA ABNORMALITIES ROULEAUX/PSEUDOAGGLUTININ

  • 91

    Wharton’s Jelly

    Group III -PROTEIN AND PLASMA ABNORMALITIES ROULEAUX/PSEUDOAGGLUTININ

  • 92

    - MISCELLANEOUS PROBLEM

    Group IV

  • 93

    Group IV -

    MISCELLANEOUS PROBLEM

  • 94

    Unexpected Antigen Reaction (bet.Forward and reverse)

    Group IV - MISCELLANEOUS PROBLEM

  • 95

    Cold Reactive Antibody

    Group IV - MISCELLANEOUS PROBLEM

  • 96

    Polyagglutination

    Group IV - MISCELLANEOUS PROBLEM